US4666845A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies to ovarian, cervical and uterine human cancers and method of diagnosis
Assignee: Memorial Sloan Kettering Cancer Center
•
Filing: 1983-12-16
•
Granted: 1987-05-19
•
Expires: 2003-12-16
Abstract
Abstract Mouse monoclonal antibodies to several cell antigens of human ovarian, cervical and endometrial carcinomas have been produced and characterized. The distribution of the antigens was determined by mixed hemagglutination assays on 153 normal and malignant cell cultures of various types, and by immunoperoxidase staining of frozen sections of 27 normal adult and 24 fetal tissues. five monoclonal antibodies representative of five classes of mAb raised to restricted ovarian, cervical and endometrial cells were tested extensively producing mAb reactive with cancer but not normal cells. One such mAb, MF116 was readily detected in the spent culture medium of metabolically radiolabeled cells. These antibodies, reacting with relatively restricted cell surface antigens, are useful in the analysis of epithelial cell differentiation, in cancer diagnosis and therapy and in tissue typing of normal or abnormal cells.
Inventors
- 👤 M. Jules Mattes
- 👤 John L. Lewis, Jr.
- 👤 Kenneth O. Lloyd
- 👤 Lloyd J. Old
- 👤 Carlos Cordon-Cardo
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 10:05
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S436/00; Y10S436/807; Y10S436/808; Y10S436/811; Y10S436/813; Y10S530/00; Y10S530/808; Y10S530/863; Y10S530/864
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
72 words
Panel of monoclonal antibodies derived by immunization with an ovarian or a uterine cell line for the diagnosis of human uterine, cervical or ovarian cancer wherein the panel consists of at least two of the monoclonal antibodies selected from the group consisting of MF 116 (HB 8411), MH 94 (HB 8413), MD 144 (HB 8409), MH 55 (HB 8412), MF 61 (HB 8410), ME 46 (HB 8430) and ME 195 (HB 8431).
Claim 2
Dependent Claim
72 words
Panel of monoclonal antibodies derived by immunization with an ovarian or a uterine cell line for the diagnosis of human uterine, cervical or ovarian cancer wherein the panel consists of at least two of the monoclonal antibodies selected from the group consisting of MF 116 (HB 8411), MH 94 (HB 8413), MD 144 (HB 8409), MH 55 (HB 8412), MF 61 (HB 8410), ME 46 (HB 8430) and ME 195 (HB 8431).
Claim 3
Dependent Claim
55 words
Method for diagnosis of malignant human ovarian, cervical or uterine cells which comprises contacting a human ovarian, cervical or uterine cell specimen, or shed antigen containing specimen thereof with one or more of the panel of monoclonal antibodies of claim 1 and immunologically detecting malignant ovarian, cervical, or uterine cells reacting with said monoclonal antibodies.
Claim 4
Dependent Claim
30 words
Monoclonal antibody panel of claim 1 wherein the immunogen cell lines are selected from the group consisting of ovarian cell lines SK-OV-3, SW 626, 2774 and uterine cell line SK-UT-1.
Claim 5
Dependent Claim
12 words
Hybridoma cell line producing any of the monoclonal antibodies of claim 1.
Claim 6
Dependent Claim
60 words
Panel of monoclonal antibodies for the diagnosis of human uterine, cervical or ovarian serous from mucinous cancer wherein the panel is selected from at least two of the group consisting of MF 116 (HB 8411), MH 94 (HB 8413), MD 144 (HB 8409), MH 55 (HB 8412), MF 61 (HB 8410), ME 46 (HB 8430) and ME 195 (HB 8431).
Claim 7
Dependent Claim
60 words
Panel of monoclonal antibodies for the diagnosis of human uterine, cervical or ovarian serous from mucinous cancer wherein the panel is selected from at least two of the group consisting of MF 116 (HB 8411), MH 94 (HB 8413), MD 144 (HB 8409), MH 55 (HB 8412), MF 61 (HB 8410), ME 46 (HB 8430) and ME 195 (HB 8431).
Claim 8
Dependent Claim
62 words
Kit for the diagnosis of ovarian, uterine or cervical cancer via shed or intact cell antigens comprisng in package form two or more of the monoclonal antibodies selected from the group consisting of MF 116 (HB 8411), MH 94 (HB 8413), MD 144 (HB 8409), MH 55 (HB 8412), MF 61 (HB 8410), ME 46 (HB 8430) and ME 195 (HB 8431).
Claim 9
Dependent Claim
62 words
Kit for the diagnosis of ovarian, uterine or cervical cancer via shed or intact cell antigens comprisng in package form two or more of the monoclonal antibodies selected from the group consisting of MF 116 (HB 8411), MH 94 (HB 8413), MD 144 (HB 8409), MH 55 (HB 8412), MF 61 (HB 8410), ME 46 (HB 8430) and ME 195 (HB 8431).
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-18 | 1990-11-17 | 1991-05-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-18 | 1994-11-17 | 1995-05-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-18 | 1998-11-17 | 1999-05-19 | $7700.00 | Window Closed / Lapsed |